The U.S. Food and Drug Administration has imposed restrictions on bluebird bio’s gene therapy Skysona, used for a rare neurological disorder, after clinical trials showed a substantial increase in cancer cases among participants. The move reflects heightened scrutiny on gene therapies concerning long-term safety profiles, particularly regarding malignancy risks. This development underscores regulatory caution amid the rapid expansion of cell and gene therapy modalities.